Background Oral fumarate (BG00012) might have dual anti-inflammatory and
neuroprotective effects. Our aim was to assess the efficacy and safety of BG00012 in …

An exploratory, prospective, open‐label study of fumaric acid esters (FAE, Fumaderm®) was
conducted in patients with relapsing–remitting multiple sclerosis (RRMS). The study …

Multiple sclerosis (MS) shares an immune-mediated origin with psoriasis. Long-term safety
and efficacy data generated in Europe from usage of fumaric acid formulations in the latter …

In the double-blind, placebo-controlled, Phase 3 DEFINE study in patients with relapsing–
remitting multiple sclerosis, oral BG-12 (dimethyl fumarate) significantly reduced the …

Objective: Currently, direct comparative evidence or head-to-head data between BG-12
(dimethyl fumarate) and other disease-modifying treatments (DMTs) is limited. This study is a …

Background: Dimethyl fumarate (DMF) demonstrated favorable benefit–risk in relapsing-
remitting multiple sclerosis (RRMS) patients in phase-III DEFINE and CONFIRM trials, and …

Background: Diroximel fumarate (DRF) is a novel oral fumarate for patients with relapsing–
remitting multiple sclerosis (RRMS). DRF and the approved drug dimethyl fumarate yield …

Dimethyl fumarate (Tecfidera®) is a novel oral therapy that has recently been approved for
the treatment of relapsing forms of multiple sclerosis (MS) and relapsing-remitting MS …

Introduction Diroximel fumarate (DRF) is a novel oral fumarate in development for patients
with relapsing forms of multiple sclerosis (MS). Clinical findings from the DRF development …

Introduction: We report safety and efficacy in patients treated with dimethyl fumarate (DMF)
for~ 9 years in ENDORSE. Lymphocyte analysis data are also reported. Methods: Incidence …